Rapid development of novel protein biomarkers using real-time immunoassays

“...optical biosensor technologies ... can effectively bridge the gap between (biomarker) discovery and early validation.” As pharmaceutical companies and regulatory agencies look to novel biomarkers to speed development and approval of novel medicines (e.g., the US FDA’s Critical Path Initiative), biomarker discoverers and developers have struggled to keep up with the demand. The ‘Omics’ revolution fed much of the early expectations and while a number of very promising DNA and RNA targets and/or signatures have been developed and validated, protein-based methods for validation have lagged far behind. With the abundance of novel technologies being developed for nucleic acids research and...